Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
mardi, octobre 20
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Beam Therapeutics Inc
BEAM
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$23.96
-0.23
-0.95%
Dern. MÀJ: Oct 20, 9:30 AM
$23.96
-0.23
-0.95%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
Beam Therapeutics Financials
Beam Therapeutics (BEAM) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Beam Therapeutics Q2 EPS $(1.18) Misses $(1.11) Estimate, Sales $490.000K Miss $16.370M Estimate
Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(1.18) per share which missed the analyst consensus estimate of $(1.11) by 6.31 percent. This is a 18 percent decrease over losses of $(1.00) per share from
Benzinga Newsdesk
PRO
Beam Therapeutics Q1 EPS $(0.91) Beats $(1.09) Estimate, Sales $31.738M Beat $10.977M Estimate
Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(0.91) per share which beat the analyst consensus estimate of $(1.09) by 16.51 percent. This is a 26.02 percent increase over losses of $(1.23) per share from
Benzinga Newsdesk
PRO
Beam Therapeutics Q4 Adj. EPS $(0.10) Beats $(0.99) Estimate, Sales $114.109M Beat $12.567M Estimate
Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.99) by 89.92 percent. This is a 90.83 percent increase over losses of $(1.09) per share from
Benzinga Newsdesk
Earnings Summary: Beam Therapeutics Q4
Benzinga Insights
Earnings Scheduled For February 24, 2026
Benzinga Insights
PRO
Beam Therapeutics Q3 EPS $(1.10) Misses $(1.05) Estimate, Sales $9.698M Miss $12.368M Estimate
Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(1.10) per share which missed the analyst consensus estimate of $(1.05) by 5.16 percent. This is a 5.98 percent increase over losses of $(1.17) per share from
Benzinga Newsdesk
